The approval is based on data primarily from two NIH-supported clinical trials.

Tuesday, December 21, 2021 NIAID Celebrates First FDA Approval of a Long-Acting HIV Prevention Medication NIAID applauds the pivotal expansion of HIV prevention options in the United States with yesterday's FDA approval of cabotegravir injected once every two months, a medication developed by ViiV Healthcare. This marks FDA's first approval of a long-acting HIV prevention medication. The approval is based on data primarily from two NIH-supported clinical trials, HPTN 083 and HPTN 084. NIAID thanks and congratulates everyone who led, conducted and participated in the research that led to this important development. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107